<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="156385">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01897792</url>
  </required_header>
  <id_info>
    <org_study_id>F101108001</org_study_id>
    <nct_id>NCT01897792</nct_id>
  </id_info>
  <brief_title>Effect of Antioxidant Vitamins on Coagulopathy and Nosocomial Pneumonia After Severe Trauma</brief_title>
  <official_title>Effect of Antioxidant Vitamins on Coagulopathy and Nosocomial Pneumonia After Severe Trauma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effect of antioxidant vitamins (vitamins C and
      E) on the development of coagulation derangements and nosocomial pneumonia after severe
      trauma in patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2013</start_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>The incidence of coagulation abnormalities, total blood product transfusions and the incidence of organ injury and ventilator-associated pneumonia.</measure>
    <time_frame>up to 3 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Coagulation parameters are evaluated using standard functional tests (prothrombin time (PT), partial thromboplastin time (PTT), fibrinogen and platelet count)and point of care functional analysis using thromboelastogram (TEG-ROTEM). Blood samples are collected upon arrival in the emergency department and at 0, 2, 4, 6, 12, and 24 hours and daily thereafter for a total of 3 days and analyzed for markers of activation of coagulation, inflammation, and levels of vitamin C/E. Mini bronchial lavage (mini-BAL) samples will be collected at 72 hours afer admission to the hospital and on any patient clinically suspected of ventilator-associated pneumonia (VAP).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Protocol violations, 28- and 60-day mortality, ventilator-free days and duration of ICU and hospital stay.</measure>
    <time_frame>up to 3 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Coagulation parameters are evaluated using standard functional tests (PT, PTT, fibrinogen and platelet count)and point of care functional analysis using thromboelastogram (TEG-ROTEM). Blood samples are collected upon arrival in the emergency department and at 0, 2, 4, 6, 12, and 24 hours and daily thereafter for a total of 3 days and analyzed for markers of activation of coagulation, inflammation, and levels of vitamin C/E. Mini bronchial lavage (mini-BAL) samples will be collected at 72 hours afer admission to the hospital and on any patient clinically suspected of VAP.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">700</enrollment>
  <condition>Coagulopathy</condition>
  <condition>Nosocomial Pneumonia</condition>
  <arm_group>
    <arm_group_label>Vitamins C and E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vitamin C (1,000 mg i.v.) and Vitamin E (1,000 IU p.o. via the naso-gastric tube) administered every 8 hours starting within one hour after admission to the Emergency department for up to 5 days or until discharge from the ICU, whichever comes first.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.9% saline and sugar pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>100 ml of 0.9% saline (for i.v. Vitamin C) and a p.o. placebo (sugar pill for the p.o. Vitamin E) administered every 8 hours starting within one hour after admission to the Emergency department for up to 5 days or until discharge from the ICU, whichever comes first.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin C</intervention_name>
    <arm_group_label>Vitamins C and E</arm_group_label>
    <other_name>ascorbic acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin E</intervention_name>
    <arm_group_label>Vitamins C and E</arm_group_label>
    <other_name>alpha-tocopherol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Saline (for Vitamin C)</intervention_name>
    <description>0.9% saline administered to mimic Vitamin C</description>
    <arm_group_label>0.9% saline and sugar pill</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (for Vitamin E)</intervention_name>
    <description>Sugar pill administered to mimic Vitamin E</description>
    <arm_group_label>0.9% saline and sugar pill</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult trauma patients admitted to the emergency department at the  University of
             Alabama at Birmingham Hospital

          -  Blunt or penetrating injury

          -  UAB highest trauma activation

        Exclusion Criteria:

          -  Age &lt; 19 years of age

          -  Patients with known bleeding diathesis or who are concurrently taking anticoagulant
             medication

          -  Patients with known liver disease

          -  Minor patients

          -  Pregnant patients (known or suspected pregnancy)

          -  Patients who are incarcerated

          -  Patients who lack a surrogate
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Francois Pittet, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Alabama at Birmingham</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jeffrey Kerby, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Alabama at Birmingham</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>LaShun L. Horn, M.S.</last_name>
    <phone>205-996-2606</phone>
    <email>lashunh@uab.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Albert Pierce, II, M.D.</last_name>
    <phone>205-975-0163</phone>
    <email>bpierce@uab.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The University of Alabama at Birmingham Hospital</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jean-Francois Pittet, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jeffrey Kerby, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Brohi K, Cohen MJ, Ganter MT, Matthay MA, Mackersie RC, Pittet JF. Acute traumatic coagulopathy: initiated by hypoperfusion: modulated through the protein C pathway? Ann Surg. 2007 May;245(5):812-8.</citation>
    <PMID>17457176</PMID>
  </reference>
  <reference>
    <citation>Brohi K, Cohen MJ, Ganter MT, Schultz MJ, Levi M, Mackersie RC, Pittet JF. Acute coagulopathy of trauma: hypoperfusion induces systemic anticoagulation and hyperfibrinolysis. J Trauma. 2008 May;64(5):1211-7; discussion 1217. doi: 10.1097/TA.0b013e318169cd3c.</citation>
    <PMID>18469643</PMID>
  </reference>
  <reference>
    <citation>Chesebro BB, Rahn P, Carles M, Esmon CT, Xu J, Brohi K, Frith D, Pittet JF, Cohen MJ. Increase in activated protein C mediates acute traumatic coagulopathy in mice. Shock. 2009 Dec;32(6):659-65. doi: 10.1097/SHK.0b013e3181a5a632. PubMed PMID: 19333141; PubMed Central PMCID: PMC3574570.</citation>
    <PMID>19333141</PMID>
  </reference>
  <reference>
    <citation>Cohen MJ, Bir N, Rahn P, Dotson R, Brohi K, Chesebro BB, Mackersie R, Carles M, Wiener-Kronish J, Pittet JF. Protein C depletion early after trauma increases the risk of ventilator-associated pneumonia. J Trauma. 2009 Dec;67(6):1176-81. doi: 10.1097/TA.0b013e3181c1c1bc.</citation>
    <PMID>20009664</PMID>
  </reference>
  <reference>
    <citation>Nathens AB, Neff MJ, Jurkovich GJ, Klotz P, Farver K, Ruzinski JT, Radella F, Garcia I, Maier RV. Randomized, prospective trial of antioxidant supplementation in critically ill surgical patients. Ann Surg. 2002 Dec;236(6):814-22.</citation>
    <PMID>12454520</PMID>
  </reference>
  <reference>
    <citation>Collier BR, Giladi A, Dossett LA, Dyer L, Fleming SB, Cotton BA. Impact of high-dose antioxidants on outcomes in acutely injured patients. JPEN J Parenter Enteral Nutr. 2008 Jul-Aug;32(4):384-8. doi: 10.1177/0148607108319808.</citation>
    <PMID>18596309</PMID>
  </reference>
  <reference>
    <citation>Brohi K, Singh J, Heron M, Coats T. Acute traumatic coagulopathy. J Trauma. 2003 Jun;54(6):1127-30.</citation>
    <PMID>12813333</PMID>
  </reference>
  <reference>
    <citation>MacLeod JB, Lynn M, McKenney MG, Cohn SM, Murtha M. Early coagulopathy predicts mortality in trauma. J Trauma. 2003 Jul;55(1):39-44.</citation>
    <PMID>12855879</PMID>
  </reference>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 6, 2014</lastchanged_date>
  <firstreceived_date>July 9, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Jean-Francois Pittet</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Blood Coagulation Disorders</mesh_term>
    <mesh_term>Hemostatic Disorders</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antioxidants</mesh_term>
    <mesh_term>Ascorbic Acid</mesh_term>
    <mesh_term>Vitamin E</mesh_term>
    <mesh_term>Alpha-Tocopherol</mesh_term>
    <mesh_term>Tocopherols</mesh_term>
    <mesh_term>Tocotrienols</mesh_term>
    <mesh_term>Vitamins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
